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Purpose. The objective was to compare the salivary protein proﬁles of saliva specimens from individuals diagnosed with invasive
ductal carcinoma of the breast (IDC) with and without lymph node involvement. Methods. Three pooled saliva specimens from
women were analyzed. One pooled specimen was from healthy women; another was from women diagnosed with Stage IIa IDC
and a specimen from women diagnosed with Stage IIb. The pooled samples were trypsinized and the peptide digests labeled with
the appropriate iTRAQ reagent. Labeled peptides from each of the digests were combined and analyzed by reverse phase capillary
chromatography on an LC-MS/MS mass spectrometer. Results. The results yielded approximately 174 diﬀerentially expressed
proteins in the saliva specimens. There were 55 proteins that were common to both cancer stages in comparison to each other
and healthy controls while there were 20 proteins unique to Stage IIa and 28 proteins that were unique to Stage IIb.
Copyright © 2009 Charles F. Streckfus et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Clinicopathologic factors such as histologic type, tumor
size, tumor grade, HER-2/neu over-expression, hormone
receptor status, and lymph node involvement are recognized
as having prognostic use in breast cancer management [1–
4]. Collectively assessed, axillary lymph node metastasis
is the most important prognostic factor predicting breast
cancer patient survival [5–7]. Currently, the best predictor
of axillary lymph node metastasis is the presence or absence
of metastasis in the sentinel lymph node.
Current methodologies for this assessment are limited
to axillary lymph node dissection and sentinel lymph
node biopsy; however, these procedures are not without
risks. For example, level I and level II axillary lymph
node dissection can be associated with upper extremity
lymph edema, wound complications, or nerve injury in a
signiﬁcant proportion of patients. Although sentinel lymph
node biopsy is far less morbid than axillary lymph node
dissection, it is not without risks or morbidity [8, 9].
Sentinel lymph node biopsy, despite its low but measurable
false negative rate, provides no information about the
presence of additional nonsentinel lymph node metastasis,
which may occur in 40% to 70% of cases [10–12]. As a
consequence, newer, more accurate, and less invasive means
of predicting axillary lymph node metastasis would greatly
improve breast cancer patient management and quality of
life.
Morphological mimicry among human malignancies is
a well-known histopathological phenomenon [11]. This is
especially true in the case of the neoplastic ductal tissues
of the breast and the salivary glands where immunostaining
revealed the presence of Her2/neu (c-erbB-2), progesterone
receptor, androgen receptor, and GCDFP-15 among these
diseased tissues [11–14]. These studies suggest that similar
molecular pathway dysfunctions may also be common
w i t h i nb o t ht i s s u e st y p e s[ 15].
Consequently, research has been performed concern-
ing the presence of cancer related proteins and protein
alterations in the secretory by products of these tissues,
that is, saliva and nipple aspirate ﬂuid (NAF) [16, 17].
Single analyte ELISA-based analyses yielded the presence of2 Journal of Oncology
soluble Her2/neu protein in both saliva and NAF; Her2/neu
concentrations were found to be elevated in both ﬂuids
secondary to the presence of carcinoma of the breast [16,
17]. Remarkably, Her2/neu protein concentrations were
also elevated in the contralateral healthy breast within the
same subject. Collectively, this line of research suggests
that cancer-related cellular signaling may aﬀect healthy
exocrine tissues and result in alterations of their secretory
by products. Likewise, EGFR and TNF-α were also found
to be present in both ﬂuids and altered in the presence
of malignant breast disease [18]. Adding further support
to this concept, both saliva and NAF were analyzed using
mass spectrometry [19–21]. These ﬂuid analyses yielded
striking similarities with respect to their protein proﬁle in
health and were altered in the presence of neoplastic disease
[19, 21].
Capitalizing on the potential of this possible relation-
ship, signiﬁcant salivary protein proﬁle comparisons and
alterations were reported in early stage breast cancer [21].
As a consequence, the purpose of this paper is to report
saliva alterations secondary to late stage IDC with a focus
concerning lymph node and nonlymph node involvement
among the IDC cohorts.
2. Methods
2.1. Design. The investigators protein proﬁled three pooled,
stimulated whole saliva specimens. One specimen consisted
of pooled saliva from 10 healthy subjects, another specimen
was a pooled saliva specimen from 10 Stage IIa (T2N0M0)
invasive ductal carcinoma patients (IDC), and the third
pooled specimen was from 10 subjects diagnosed with Stage
IIb (T2N1M0) invasive ductal carcinoma [22]. The cancer
cohorts were estrogen, progesterone, and Her2/neu receptor
status negative as determined by the pathology report.
Histological grade was not available for this study. The
subjects were matched for age and race and were nontobacco
users.
The participating subjects were given an explanation
about their participation rights and signed an IRB consent
form. The saliva specimens and related patient data are
nonlinked and bar coded in order to protect patient con-
ﬁdentiality. This study was performed under the UTHSC
IRB approved protocol number HSC-DB-05-0394. All pro-
cedures were in accordance with the ethical standards of the
UTHSC IRB and with the Helsinki Declaration of 1975, as
revised in 1983.
2.2. Saliva Collection and Sample Preparation. Stimulated
whole salivary gland secretion is based on the reﬂex response
occurring during the mastication of a bolus of food. Usually,
a standardized bolus (1 gram) of paraﬃn or a gum base
(generously provided by the Wrigley Co., Peoria, IL) is given
to the subject to chew at a regular rate. The individual, upon
suﬃcient accumulation of saliva in the oral cavity, expecto-
rates periodically into a preweighed disposable plastic cup.
This procedure is continued for a period of ﬁve minutes.
The volume and ﬂow rate is then recorded along with a brief
description of the specimen’s physical appearance [23]. The
cup with the saliva specimen is reweighed and the ﬂow rate
determined gravimetrically. The authors recommend this
salivary collection method with the following modiﬁcations
for consistent protein analyses [24]. A protease inhibitor
from Sigma Co (St. Louis, MI, USA) is added along with
enough orthovanadate from a 100mM stock solution to
bring its concentration to 1mM. The treated samples were
centrifuged for 10 minutes at top speed in a table top
centrifuge. The supernatant was divided into 1mL aliquots
and frozen at −80◦C.
2.3. LC-MS/MS Mass Spectroscopy with Isotopic Labeling.
Recent advances in mass spectrometry, liquid chromatog-
raphy, analytical software, and bioinformatics have enabled
the researchers to analyze complex peptide mixtures with the
ability to detect proteins diﬀering in abundance by over 8
orders of magnitude [25]. One current method is isotopic
labeling coupled with liquid chromatography tandem mass
spectrometry (IL-LC-MS/MS) to characterize the salivary
proteome [26]. The main approach for discovery is a mass
spectroscopy-basedmethod that usesisotope coding ofcom-
plex protein mixtures such as tissue extracts, blood, urine, or
saliva to identify diﬀerentially expressed proteins [27]. The
approach readily identiﬁes changes in the level of expres-
sion, thus permitting the analysis of putative regulatory
pathways providing information regarding the pathological
disturbances in addition to potential biomarkers of disease.
The analysis was performed on a tandem QqTOF QStar
XL mass spectrometer (Applied Biosystems, Foster City, CA,
USA) equipped with an LC Packings (Sunny vale, CA, USA)
HPLC for capillary chromatography. The HPLC is coupled
to the mass spectrometer by a nanospray ESI head (Protana,
Odense, Denmark) for maximal sensitivity [16]. The advan-
tage of tandem mass spectrometry combined with LC is
enhanced sensitivity and the peptide separations aﬀorded
b yc h r o m a t o g r a p h y .T h u se v e ni nc o m p l e xp r o t e i nm i x t u r e s
MS/MS data can be used to sequence and identify peptides
by sequence analysis with a high degree of conﬁdence [21,
25, 26, 28].
Isotopic labeling of protein mixtures has proven to be a
useful technique for the analysis of relative expression levels
of proteins in complex protein mixtures such as plasma,
saliva urine, or cell extracts. There are numerous methods
that are based on isotopically labeled protein modifying
reagents to label or tag proteins to determine relative or
absolute concentrations in complex mixtures. The higher
resolutionoﬀeredbythetandemQq-TOFmassspectrometer
is ideally suited to isotopically labeled applications [21, 26,
29, 30].
Applied Biosystems recently introduced iTRAQ reagents
[26, 29, 30], which are amino reactive compounds that are
used to label peptides in a total protein digest of a ﬂuid such
as saliva. The real advantage is that the tag remains intact
through TOF-MS analysis; however, it is revealed during
collision-induced dissociation by MSMS analysis. Thus in
the MSMS spectrum for each peptide there is a ﬁngerprint
indicating the amount of that peptide from each of theJournal of Oncology 3
diﬀerent protein pools. Since virtually all of the peptides in
a mixture are labeled by the reaction, numerous proteins in
complex mixtures are identiﬁed and can be compared for
their relative concentrations in each mixture. Thus even in
complex mixtures there is a high degree of conﬁdence in the
identiﬁcation.
2.4. Salivary Protein Analyses with iTRAQ. Brieﬂy, the saliva
sampleswerethawedandimmediatelycentrifugedtoremove
insoluble materials. The supernatant was assayed for protein
using the Bio-Rad protein assay (Hercules, CA, USA) and an
aliquot containing 100μg of each specimen was precipitated
with 6 volumes of −20◦C acetone. The precipitate was
resuspended and treated according to the manufacturers
instructions. Protein digestion and reaction with iTRAQ
labels was carried out as previously described and according
to the manufacturer’s instructions (Applied Biosystems,
Foster City, CA). Brieﬂy, the acetone precipitable protein
was centrifuged in a table—top centrifuge at 15,000 × gf o r
20 minutes. The acetone supernatant was removed and the
pellet resuspended in 20uL dissolution buﬀer. The soluble
fraction was denatured and disulﬁdes reduced by incubation
in the presence of 0.1% SDS and 5mM TCEP (tris-(2-
carboxyethyl) phosphine)) at 60◦C for one hour. Cysteine
residues were blocked by incubation at room temperature
for10minuteswithMMTS(methylmethane-thiosulfonate).
Trypsin was added to the mixture to a protein : trypsin ratio
of 10:1. The mixture was incubated overnight at 37◦C. The
protein digests were labeled by mixing with the appropriate
iTRAQ reagent and incubating at room temperature for
one hour. On completion of the labeling reaction, the four
separate iTRAQ reaction mixtures were combined. Since
there are a number of components that can interfere with the
LCMSMS analysis, the labeled peptides are partially puriﬁed
by a combination of strong cation exchange followed by
reverse phase chromatography on preparative columns. The
combined peptide mixture is diluted 10-fold with loading
buﬀer (10mM KH2PO4 in 25% acetonitrile at pH 3.0) and
applied by syringe to an ICAT Cartridge-Cation Exchange
column (Applied Biosystems, Foster City, CA) column that
has been equilibrated with the same buﬀer. The column is
washedwith1mLloadingbuﬀertoremovecontaminants.To
improvetheresolutionofpeptidesduringLCMSMSanalysis,
the peptide mixture is partially puriﬁed by elution from the
cationexchangecolumnin3fractions.Stepwiseelutionfrom
the column is achieved with sequential 0.5mL aliquots of
10mM KH2PO4 at pH 3.0 in 25% acetonitrile containing
116mM, 233mM, and 350mM KCl, respectively. The frac-
tions are evaporated by Speed Vac to about 30% of their
volume to remove the acetonitrile and then slowly applied
to an Opti-Lynx Trap C18 100 uL reverse phase column (All-
tech, Deerﬁeld, IL) with a syringe. The column was washed
with 1mL of 2% acetonitrile in 0.1% formic acid and eluted
in one fraction with 0.3mL of 30% acetonitrile in 0.1%
formic acid. The fractions were dried by lyophilization and
r e s u s p e n d e di n1 0u L0 . 1 %f o r m i ca c i di n2 0 %a c e t o n i t r i l e .
Each of the three fractions was analyzed by reverse phase
LCMSMS.
Table 1
Summary of protein expression proﬁles
Comparison Up Regulated Down Regulated Total Markers
Stage IIa versus 34 41 75
healthy
Stage IIb versus 38 45 83
healthy
Totals 72 86 158
Stage IIa compared to stage IIb
Common proteins 24 31 55
Diﬀering proteins 24 24 48
Totals 48 55 83
Protein function
1 Signaling
2T r a n s p o r t
3 Oxygen transporter
4 Inhibitor of cysteine proteases
5R e d o x p r o t e i n
6 Lipid degradation
7 Endocytosis
8 PRP isopeptide binding protein
9 Cancer antigen
10 DNA repair
11 Unknown
12 Cytoskeleton
13 Clotting
14 Immune response
15 Enzymes
16 Calcium binding
17 Enzyme inhibitor
18 Apoptosis
19 Antibacterial
20 Regulatory protein
19
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Figure 1: It represents protein function.
2.5. Reverse Phase LCMSMS. The desalted and concentrated
peptide mixtures were quantiﬁed and identiﬁed by nano-
LCMS/MS on an API QSTAR XL mass spectrometer (ABS
Sciex Instruments) operating in positive ion mode. The
chromatographicsystemconsistsofanUltiMatenano-HPLC
and FAMOS autosampler (Dionex LC Packings). Peptides
were loaded on a 75cm x 10cm, 3mm fused silica C18
capillary column, followed by mobile phase elution: buﬀer
(A) 0.1% formic acid in 2% acetonitrile/98% Milli-Q water4 Journal of Oncology
and buﬀer (B): 0.1% formic acid in 98% acetonitrile/2%
Milli-Q water. The peptides were eluted from 2% buﬀer B to
30%buﬀerBover180minutesataﬂowrate220nL/min.The
LC eluent was directed to a NanoES source for ESI/MS/MS
analysis. Using information-dependent acquisition, peptides
were selected for collision induced dissociation (CID) by
alternating between an MS (1 second) survey scan and
MS/MS (3 seconds) scans. The mass spectrometer automat-
ically chooses the top two ions for fragmentation with a 60-
second dynamic exclusion time. The IDA collision energy
parameters were optimized based upon the charge state and
mass value of the precursor ions. In each saliva sample set
there are three separate LCMSMS analyses.
2.6. Bioinformatics. The accumulated MSMS spectra are
analyzed by ProQuant and ProGroup software packages
(Applied Biosystems) using the SwissProt database for
protein identiﬁcation. The ProQuant analysis was carried
out with a 75% conﬁdence cutoﬀ with a mass deviation of
0.15 Da for the precursor and 0.1 Da for the fragment ions.
The ProGroup reports were generated with a 95% conﬁ-
dence level for protein identiﬁcation. Protein Pilot software
package was used to assess the data produced from the mass
spectrometry analyses. The Venn diagrams were constructed
using the NIH software program (http://ncrr.pnl.gov).
Graphic comparisons with log conversions and error bars
for protein expression were produced using the ProQuant
software. Descriptive statistics were performed using SPSS
statistical software.
3. Results
Tables 1–5 summarize the results of the mass spectrometry
analysis of the pooled salivary specimens and illustrate
protein comparisons between Stage IIa versus healthy and
Stage IIb versus healthy. The results identiﬁed and compared
approximately 174 diﬀerentially expressed proteins in the
saliva specimens. Of the 174 proteins, 158 (91%) were
signiﬁcant at an alpha level of P<.05 with a 95% conﬁdence
level. The mean percent peptide coverage for the complete
panel proteins was 63.5% (±19.6) with a range of 35% to
96.5% coverage. The median value was 67.7% coverage.
ThepiechartinFigure 1illustratesthepercentageofpro-
teins according to protein function. There were 55 proteins
that were common to both cancer stages in comparison to
each other while there were 20 proteins unique to Stage IIa
and 28 proteins that were unique to Stage IIb (Table 1).
Figure 2 represents a Venn diagram of the overlapping
proteins between the three groups of women. Figure 3 illus-
trates the comparison of the log ratio of the relative intensity
(cancer/control)of the proteins which were common to both
Stage IIa and Stage IIb while Figure 4 shows the proteins that
were diﬀerent between the two groups. It is worth noting
that in Figure 3 the stage IIb protein ratios (X1.675; ±0.471)
are greater than the stage IIa ratios (X1.431; ±0.469) for the
same proteins. Consequently, a paired t-test was performed
comparing the two groups of values. The diﬀerence in the
mean values between the two groups is greater than would
Stage IIa (n = 34) Stage IIb (n = 38)
n = 10 n = 24 n = 14 Upregulated proteins
(a)
Stage IIa (n = 41) Stage IIb (n = 45)
n = 10 n = 31 n = 14 Downregulated proteins
(b)
Figure 2: It represents a Venn diagram of the overlapping proteins
within stage IIa and stage IIb.
be expected by chance; there is a statistically signiﬁcant
diﬀerence (t =− 2.882; P<. 008).
Tables 2 and 3 represent the up- (n = 34) and down-
(n = 41) regulated proteins for the pooled saliva sample
composedofindividualsdiagnosedwithaStageIIaIDC.The
fold-increase of protein and P-values are also presented. As
shown in Tables 2 and 3, 40 of the 75 proteins (53%) were
signiﬁcant at the P<.001 to P<.0001 levels.
Tables 4 and 5 are a list of the up- (n = 38) and down-
(n = 45) regulated proteins observed in the Stage IIb cancer
as compared to healthy controls. Of these 83 diﬀerentially
expressed proteins, 54 (65%) were signiﬁcant at the P<.001
to P<.0001 levels. There were 6 proteins that exhibited a 2.0
orgreaterfoldincreaseinproteinlevelintheStageIIbcancer
cohort as compared to the control subjects.
4. Discussion
To the best of our knowledge this is the ﬁrst attempt
to determine salivary protein proﬁle alterations related to
lymphovascular invasion. As a consequence we have only a
few references by which to compare our data.
The proteins listed in Tables 2–4 are common to saliva
and are listed in references concerning salivary proteomics of
wholesalivaandthoseconstituentscontributedbyindividual
gland secretions [21, 31–34]. Likewise, many of the proteins
are common to those identiﬁed in proteomic studies of
cancer cell lines and serum or plasma from individuals
diagnosed with IDC [21, 27, 35–39]. Additionally, there
is a proteomic study by Pei et al. [40] that compared pro-
teomic tissue protein proﬁles from paired normal tissue to
malignant tissues with and without lymphovascular invasionJournal of Oncology 5
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Figure 3: Diﬀerential expressions of salivary proteins common to
both stage IIa and stage IIb.
[40].Theirresultsyielded25diﬀerentiallyexpressedproteins
among node positive and node negative, adenocarcinoma,
colorectal cancer patients. From the list of 25 proteins that
were diﬀerentially expressed when compared to a normal
control by Pei et al., we matched 8 (32%) of them. These
proteins were Apo-A1 protein, vimentin, cytokeratin-8,
glutathione s-transferase, keratin 1, fructose-bisphosphate
aldolase, alpha enolase, and transferring precursor [40]. Pei
also reports Annexin II and IV while we found members
Annexin I and III of the same family of proteins. Pei et al.
identiﬁed four proteins which were diﬀerentially expressed.
These were heat shock protein 27 (HSP-27), glutathione S-
transferase (GST), Annexin II, and liver-fatty acid binding
protein (L-FABP). The authors of this manuscript found 48
diﬀerentially expressed proteins (Figure 4) which included
GST and a family member of the fatty acid binding proteins,
epidermal-fatty acid binding protein.
A second by Li et al. [41] used metastatic (lymph nodes)
breast cancer cell lines that they developed in order to
produce protein proﬁle comparisons [41]. Comparative
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Figure 4: Diﬀerential expressions of salivary proteins that were not
common to both stage IIa and stage IIb.
proteomic analysis using 2-DE and LC-IT-MS revealed that
102 protein gel spots were altered more than three-fold
between the variant and its parental counterpart. Using
SEQUEST with uninterpreted tandem mass raw data, they
f o u n de l e v e nd i ﬀerentially expressed protein spots that were
identiﬁed with high conﬁdence. The proteins were identiﬁed
as Cathepsin D precursor, peroxiredoxin 6 (PDX6), heat
shock protein 27 (HSP27), HSP60, tropomyosin 1 (sent in
the highly metastatic variant, whereas alpha B-crystalline
(CRAB) was only detected in its parTPM1), TPM2, TPM3,
TPM4, 14-3-3 protein epsilon, and tumor protein D54.
The proteins were preental counterpart [41]. As shown in
Tables 2–5, we identiﬁed a number of the same proteins.
For example, the 14-3-3, tropomyosin and the peroxiredoxin
family of proteins were found to be altered in the saliva of
our late stage cancer proﬁles as well. Of particular interest is
the fact that these proteins were not altered in the proﬁles of
early stage cancer, that is, Stage 0 and Stage I performed by
the authors of this manuscript [21, 42].
5. Conclusions
The authors have examined the salivary proteome that is
altered in the presence of carcinoma of the breast with and
without lymph node metastasis. We do not want to over6 Journal of Oncology
Table 2: Upregulated salivary proteins for stage IIa (n = 34).
Accession Gene ID Name Ratio P value
P02763 A1AG1 Alpha-1 acid glycoprotein 1 precursor (AGP 1) 1.3229 .0127
P01023 A2MG Alpha-2 macroglobulin precursor 1.1446 .0324
P07108 ACBP AcylCoA binding protein 1.2264 .0254
P02768 ALBU Serum albumin precursor 1.3677 .0000
P04745 AMYS Salivary alpha amylase precursor 1.3564 .0000
P61769 B2MG Beta-2 microglobulin precursor 1.1463 .0465
P04040 CATA Catalase 1.0918 .0183
P01024 CO3 Complement C3 precursor 1.1698 .0194
P01040 CYTA CystatinA (SteﬁnA) (CystatinAS) 1.4403 .0005
P04080 CYTB CystatinB (SteﬁnB) 1.1440 .0108
P06733 ENOA Alphaenolase 1.2626 .0000
Q01469 FABPE Fatty acidbinding protein, epidermal (EFABP) 1.3126 .0022
Q5VTM1 fAM25 Protein FAM25 1.3647 .0165
P02765 FETUA Alpha-2HS glycoprotein precursor 1.3101 .0129
P00738 HPT Haptoglobin precursor 1.5562 .0000
P01781 HV320 Ig heavy chain VIII region GAL 1.3879 .0336
P01876 IGHA1 Ig alpha1 chain C region 1.4641 .0000
P01591 IGJ Immunoglobulin J chain 1.2429 .0002
P35527 K1C9 Keratin, type I cytoskeletal 9 1.1629 .0279
P01834 KAC Ig kappa chain C region 1.0953 .0016
P06870 KLK1 Kallikrein1 precursor 1.6991 .0000
P06309 KV205 Ig kappa chain VII region GM607 precursor 1.2300 .0131
P18135 KV312 Ig kappa chain VIII region HAH precursor 1.2637 .0077
P01842 LAC Ig lambda chain C regions 1.0933 .0004
P31025 LCN1 Lipocalin1 precursor 1.3213 .0000
P80188 NGAL Neutrophil gelatinase associated lipocalin precursor (Oncogene 24p3) 1.5325 .0000
P01833 PIGR Hepatocellular carcinomaassociated protein TB6 1.3233 .0000
P26447 S10A4 Protein S100A4 (S100 calciumbinding protein A4) 1.1539 .0027
P31151 S10A7 Protein S100A7 (Psoriasin) 3.3466 .0000
P35321 SPR1A Corniﬁn-A (19kDa pancornulin) 1.4452 .0093
Q9UBC9 SPRR3 Corniﬁn beta (22kDa pancornulin) 1.2787 .0000
P20061 TCO1 Transcobalamin1 precursor 1.1222 .0383
P62328 TYB4 Thymosin beta 4 2.1483 .0007
P62988 UBIQ Ubiquitin 1.3427 .0424
emphasize the ﬁndings at this point, but we are encouraged
to ﬁnd that these protein proﬁles are found to be altered in
the supernants from cancer tissues which provide additional
support to our ﬁndings.
The authors urge the exploration of saliva proteomics
for in vivo systems modeling of carcinoma of tissues of
ectodermal origin. Saliva can also be described as a media
which provides “real-time” results [43]. The ﬂuid is continu-
ally produced and excreted in an open-ended circuit, unlike
blood which exists in a “closed-loop.” Blood, a circulating
media, may contain proteins that are a day, a week, or a
month old as well as proteins which have passed numerous
times through many organ systems or have been excreted
[43]. Saliva, with its continuous ﬂow, is not subject to
the aforementioned eﬀects. Consequently, saliva and nipple
aspirates may be a more useful than blood as the protein
proﬁles of these ﬂuids easier to assay than blood and are both
altered in the presence of malignant diseases [16, 43].
Further study is required to determine their diagnostic
utility. The authors plan to validate the protein biomarkers
by western blot using commercially available antibodies.
ELISA will also be used to assay a larger sample size and
determine the sensitivity and speciﬁcity of the biomarkers. It
is the hope of the investigators that this preliminary research
will establish the foundation for a “point-of-care” test for
clinical decision making in the treatment of carcinoma of the
breast.
6. Disclosure Statement
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Table 3: Downregulated salivary proteins for stage IIa (n = 41).
Accession Gene ID Name Ratio P value
P31947 1433S 14-3-3 protein sigma (Epithelial cell marker protein 1) 0.7921 .0043
P04075 ALDOA Fructose-bisphosphate aldolase 0.7036 .0000
Q8N4F0 BPIL1 Lung and nasal epith, carcinoma-assoc. protein 2 0.7465 .0002
P23280 CAH6 Carbonic anhydrase 6 precursoranhydrase 0.7871 .0000
P54108 CRIS3 Cysteine-rich secretory protein 3 precursor (CRISP-3) 0.7846 .0003
P01034 CYTC Cystatin-C precursor (Cystatin-3) 0.7108 .0000
P28325 CYTD Cystatin-D precursor (Cystatin-5) 0.6047 .0000
P01037 CYTN Cystatin-SN precursor 0.3200 .0000
P01036 CYTS Cystatin-S precursor (Cystatin-4) 0.3385 .0000
P09228 CYTT Cystatin-SA precursor (Cystatin-S5) 0.4153 .0000
Q9UGM3 DMBT1 Deleted in malignant brain tumors 1 protein precursor (Glycoprotein 340) 0.7910 .0050
P02671 FIBA Fibrinogen alpha chain precursor [Contains: Fibrinopeptide A] 0.8964 .0104
P09211 GSTP1 Glutathione S-transferase P 0.8782 .0261
Q8IUE6 H2A2B Histone H2A 0.5435 .0211
Q99880 H2B1L Histone H2B type 1-L 0.5576 .0008
P62805 H4 Histone H4 0.4195 .0000
P15515 HIS1 Histatin-1 precursor 0.3152 .0340
P01857 IGHG1 Ig gamma-1 chain C region 0.9173 .0306
P13646 K1C13 Keratin, type I cytoskeletal 13 (Cytokeratin-13) 0.6395 .0011
P08779 K1C16 Keratin, type I cytoskeletal 16 (Cytokeratin-16) 0.6220 .0001
P61626 LYSC Lysozyme C precursor 0.4121 .0000
P01871 MUC Ig mu chain C region 0.6877 .0000
Q9HC84 MUC5B Mucin-5B precursor 0.6404 .0000
P80303 NUCB2 Nucleobindin-2 precursor (Gastric cancer antigen Zg4) 0.6836 .0000
P22079 PERL Lactoperoxidase precursor 0.8196 .0000
P05164 PERM Myeloperoxidase precursor 0.6894 .0000
P12273 PIP Prolactin-inducible protein precursor 0.6382 .0000
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B precursor 0.8769 .0326
P02812 PRB2 Basic salivary proline-rich protein 2 0.5422 .0000
Q06830 PRDX1 Peroxiredoxin-1 0.7296 .0020
P02810 PRPC Salivary acidic proline-rich phosphoprotein 1/2 precursor 0.8848 .0000
P06703 S10A6 Protein S100-A6 (Growth factor-inducible protein 2A9) 0.8926 .0051
P05109 S10A8 Protein S100-A8 (S100 calcium-binding protein A8) 0.5888 .0000
P06702 S10A9 Protein S100-A9 (S100 calcium-binding protein A9) 0.6622 .0000
P31949 S10AB Protein S100-A11 (S100 calcium-binding protein A11) 0.6526 .0017
Q96DR5 SPLC2 Lung and nasal epith. carcinoma-assoc. protein 2 precursor 0.3270 .0000
Q08188 TGM3 Protein-glutamine gamma-glutamyltransferase E precursor 0.7454 .0168
P29401 TKT Transketolase 0.8236 .0351
P06753 TPM3 Tropomyosin alpha-3 chain 0.7809 .0016
P02788 TRFL Lactotransferrin precursor 0.8118 .0000
P08670 VIME Vimentin 0.7728 .01908 Journal of Oncology
Table 4: Upregulated salivary proteins for stage IIb (n = 38).
Accession Gene ID Name Ratio P value
P02763 A1AG1 Alpha-1-acid glycoprotein 1 precursor (AGP 1) 1.8128 .0003
P01023 A2MG Alpha-2-macroglobulin precursor (Alpha-2-M) 1.7279 .0000
P02768 ALBU Serum albumin precursor 1.9149 .0000
P12429 ANXA3 Annexin A3 (Annexin III) 1.3144 .0058
P02647 APOA1 Apolipoprotein A-I precursor (Apo-AI) 1.2233 .0012
P00915 CAH1 Carbonic anhydrase 1 3.3424 .0356
P62158 CALM Calmodulin (CaM) 1.5783 .0391
P04040 CATA Catalase 1.4806 .0007
P01024 CO3 Complement C3 precursor 1.3391 .0000
P06733 ENOA Alpha-enolase 1.4856 .0000
P02765 FETUA Alpha-2-HS-glycoprotein precursor (Fetuin-A) 1.4004 .0007
P52566 GDIS Rho GDP-dissociation inhibitor 2 (Rho GDI 2) 1.3866 .0046
P69905 HBA Hemoglobin subunit alpha (Hemoglobin alpha chain) 1.8916 .0000
P68871 HBB Hemoglobin subunit beta (Hemoglobin beta chain) 1.8326 .0000
P02790 HEMO Hemopexin precursor (Beta-1B-glycoprotein) 2.2691 .0001
P00738 HPT Haptoglobin precursor 2.3331 .0000
P01762 HV301 Ig heavy chain V-III region TRO 1.3350 .0262
P01781 HV320 Ig heavy chain V-III region GAL 1.6357 .0259
P01876 IGHA1 Ig alpha-1 chain C region 1.4384 .0000
P01877 IGHA2 Ig alpha-2 chain C region 1.1678 .0288
P01857 IGHG1 Ig gamma-1 chain C region 1.4955 .0000
P01859 IGHG2 Ig gamma-2 chain C region 1.5578 .0000
P01591 IGJ Immunoglobulin J chain 1.3564 .0000
P01834 KAC Ig kappa chain C region 1.2156 .0000
P06870 KLK1 Kallikrein-1 precursor 1.6222 .0000
P18135 KV312 Ig kappa chain V-III region HAH precursor 1.4020 .0009
P01842 LAC Ig lambda chain C regions 1.3162 .0000
P31025 LCN1 Lipocalin-1 precursor 2.1725 .0000
P80188 NGAL Neutrophil gelatinase-assoc. lipocalin precursor (Oncogene 24p3) 1.6181 .0000
P01833 PIGR Hepatocellular carcinoma-associated protein TB6 1.2753 .0000
P31151 S10A7 Protein S100-A7 (S100 calcium-binding protein A7) 2.2683 .0000
P35321 SPR1A Corniﬁn-A(SPR-IA) 1.6742 .0084
Q9UBC9 SPRR3 Corniﬁn beta (22 kDa pancornulin) 1.5506 .0000
P37837 TALDO Transaldolase 1.3811 .0053
P20061 TCO1 Transcobalamin-1 precursor (Transcobalamin I) 1.2262 .0001
P02787 TRFE Serotransferrin precursor (Transferrin) 1.5744 .0000
P62328 TYB4 Thymosin beta-4 (T beta 4) 3.3412 .0003
P62988 UBIQ Ubiquitin 1.5925 .0055Journal of Oncology 9
Table 5: Downregulated salivary proteins for stage IIb (n = 45).
Accession Gene ID Protein Name Ratio P value
P31947 1433S 14-3-3 protein sigma (Stratiﬁn) (Epithelial cell marker protein 1) 0.5486 .0000
P63104 1433Z 14-3-3 protein zeta/delta (Protein kinase C inhibitor protein 1) 0.5718 .0378
P04075 ALDOA Fructose-bisphosphate aldolase A (Lung cancer antigen NY-LU-1) 0.7080 .0001
P19961 AMYC Alpha-amylase 2B precursor 0.6840 .0020
P04745 AMYS Salivary alpha-amylase precursor 0.9302 .0042
P04083 ANXA1 Annexin A1 (p35) 0.8105 .0080
P23280 CAH6 Carbonic anhydrase 6 precursor 0.4900 .0000
P10909 CLUS Clusterin precursor (Complement-associated protein SP-40,40) 0.7704 .0252
P04080 CYTB Cystatin-B (Steﬁn-B) (Liver thiol proteinase inhibitor) 0.8705 .0007
P01034 CYTC Cystatin-C precursor (Cystatin-3) 0.5621 .0000
P28325 CYTD Cystatin-D precursor (Cystatin-5) 0.4856 .0000
P01037 CYTN Cystatin-SN precursor (Cystatin-1) 0.2323 .0000
P01036 CYTS Cystatin-S precursor (Cystatin-4) 0.2437 .0000
P09228 CYTT Cystatin-SA precursor (Cystatin-S5) 0.3033 .0000
Q02487 DSC2 Desmocollin-2 precursor (Desmosomal glycoprotein II and III) 0.7029 .0063
P06744 G6PI Glucose-6-phosphate isomerase (SA-36)—(Human) 0.5118 .0013
P09211 GSTP1 Glutathione S-transferase P 0.7563 .0001
Q8IUE6 H2A2B Histone H2A type 2-B 0.5699 .0058
Q99880 H2B1L Histone H2B type 1-L (H2B.c) 0.6841 .0373
P62805 H4 Histone H4 0.3745 .0000
P15515 HIS1 Histatin-1 precursor (Histidine-rich protein 1) 0.2237 .0032
P30740 ILEU Leukocyte elastase inhibitor (Serpin B1) 0.9203 .0418
P13646 K1C13 Keratin, type I cytoskeletal 13 (Cytokeratin-13) 0.4247 .0000
P08779 K1C16 Keratin, type I cytoskeletal 16 (Cytokeratin-16) 0.4900 .0000
P02538 K2C6A Keratin, type II cytoskeletal 6A (Cytokeratin-6A) 0.6744 .0019
P61626 LYSC Lysozyme C precursor 0.6646 .0000
P01871 MUC Ig mu chain C region 0.7992 .0000
Q9HC84 MUC5B Mucin-5B precursor (Mucin-5 subtype B, tracheobronchial) 0.9357 .0260
P80303 NUCB2 Nucleobindin-2 precursor (Gastric cancer antigen Zg4) 0.4934 .0000
P07237 PDIA1 Protein disulﬁde-isomerase precursor (p55) 0.8132 .0205
P22079 PERL Lactoperoxidase precursor 0.6879 .0000
P05164 PERM Myeloperoxidase precursor 0.7856 .0049
P12273 PIP Prolactin-inducible protein precursor (gp17) 0.4659 .0000
P62937 PPIA Peptidyl-prolyl cis-trans isomerase A 0.8031 .0091
P23284 PPIB Peptidyl-prolyl cis-trans isomerase B precursor 0.7089 .0006
P02812 PRB2 Basic salivary proline-rich protein 2 (Salivary proline-rich protein) 0.4204 .0000
Q06830 PRDX1 Peroxiredoxin-1 0.6877 .0006
P02810 PRPC Salivary acidic proline-rich phosphoprotein 1/2 precursor (PRP-1/PRP-2) 0.6861 .0000
P05109 S10A8 Protein S100-A8 (S100 calcium-binding protein A8) (Calgranulin-A) 0.8042 .0000
Q96DR5 SPLC2 Lung and nasal epith. carcinoma-assoc. protein 2 precursor 0.2322 .0000
P10599 THIO Thioredoxin (Trx) (ATL-derived factor) 0.8003 .0003
P06753 TPM3 Tropomyosin alpha-3 chain (Tropomyosin-3) 0.8990 .0215
P02788 TRFL Lactotransferrin precursor 0.7072 .0000
P08670 VIME Vimentin 0.7717 .0277
P25311 ZA2G Zinc-alpha-2-glycoprotein precursor (Zn-alpha-2-glycoprotein) 0.8543 .000010 Journal of Oncology
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